Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

CAPS Rating: 4 out of 5

Discovers, develops and intend to commercialize drugs for the treatment of neurological and endocrine-related diseases and disorders. Product candidates will target insomnia, anxiety, depression, cancer, diabetes, and multiple sclerosis.

Recs

0
Player Avatar pisspoorpicks (< 20) Submitted: 2/2/2013 11:10:16 PM : Outperform Start Price: $9.21 NBIX Score: +17.85

06/30/2013 Phase 2 trial of elagolix in the treatment of uterine fibroids is expected to be completed in 1H 2013.

06/30/2013 Data from Phase 2b trial of NBI-98854 in tardive dyskinesia patients due 2Q 2013 (Kinect 1 Study).

06/30/2013 Data from second Phase 2b trial of NBI-98854 in tardive dyskinesia patients due mid 2013 (Kinect 2 Study).

Featured Broker Partners


Advertisement